Sytabz Meditech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 125.69%
- Profit Growth -20.86%
- Ebitda -16.39%
- Net Worth -76.38%
- Total Assets 2.95%
About Sytabz Meditech
Sytabz Meditech Private Limited (SMPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 May 2018 (Six years and eight months 27 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Rajeeva Kanthan, Addekoppa Ramesh, Suma Krishnamurthy, and Three other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33100KA2018PTC113549
- Company No.
113549
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Sytabz Meditech?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeeva Kanthan  | Director | 23-Nov-2018 | Current |
| Addekoppa Ramesh | Director | 30-May-2018 | Current |
| Suma Krishnamurthy | Director | 30-May-2018 | Current |
| Sudha Narayanaswamy | Director | 23-Nov-2018 | Current |
| Gurukrupa Rao | Director | 01-Aug-2018 | Current |
| Deeksha Nagaraju | Director | 25-Aug-2021 | Current |
Financial Performance of Sytabz Meditech.
Sytabz Meditech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 125.69% increase. The company also saw a substantial fall in profitability, with a 20.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 76.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sytabz Meditech?
In 2022, Sytabz Meditech had a promoter holding of 93.33% and a public holding of 6.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Global Dicon LlpRajeeva Kanthan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sytabz Meditech?
Unlock and access historical data on people associated with Sytabz Meditech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sytabz Meditech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sytabz Meditech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
